NTRR — what changed in the latest 10-Q
A section-by-section comparison of NTRR's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2024-08-07 vs the prior 10-Q · 2023-12-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +3 | −9 | ~5 | 10 |
| Controls & procedures | Text added/removed | 0 | 0 | ~4 | 3 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Risk factors, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2024-08-07
During the three months ended April 30, 2024, we recognized revenue of $32,375 and cost of goods sold of $1,420. For the three months ended April 30, 2024, revenue from consulting income from business development consulting services to one customer $29,420 and revenue from sales of CBD products tota…
Interest expense was $867 and $199 for the three months ended April 30, 2024 and 2023, respectively.
At April 30, 2024, we had cash on hand of $333. We have negative working capital of $987,030. Net cash used in operating activities for the three months ended April 30, 2024 was $1,299. The Company had net cash provided by investing and financing activities of $0 for the three months ended April 30,…
Text removed vs the prior filing · source: 10-Q · 2023-12-15
During the three months ended October 31, 2023, we recognized revenue of $1,311 and cost of goods sold of $722 related to the sales of CBD products. During the three months ended October 31, 2022, we recognized revenue of $23,383 and cost of goods sold of $12,708 related to the sales of CBD products…
Interest expense was $2,258 and $15,718 for the three months ended October 31, 2023, and 2022, respectively. The decrease in interest expense was related to the settlement of outstanding convertible notes payable in the prior year.
Nine months ended October 31, 2023, compared to the nine months ended October 31, 2022.
During the nine months ended October 31, 2023, we recognized revenue of $11,478 and cost of goods sold of $6,403 related to the sales of CBD products. During the nine months ended October 31, 2022, we recognized revenue of $62,077 and cost of goods sold of $29,725 related to the sales of CBD product…
We recognized depreciation expense of $41,816 and $59,179 for the nine months ended October 31, 2023, and 2022 related to the Company’s property and equipment.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice